10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Mon, 29-Dec 4:05 PM ET)
PRNewswire (Tue, 18-Nov 9:01 AM ET)
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
PRNewswire (Tue, 11-Nov 4:05 PM ET)
10x Genomics Projects Sequential Revenue Growth Despite Ongoing Operating Losses
Market Chameleon (Fri, 7-Nov 6:19 AM ET)
10x Genomics Reports Third Quarter 2025 Financial Results
PRNewswire (Thu, 6-Nov 4:06 PM ET)
10x Genomics’ Next-Gen Chromium Flex Sets New Standard for Scalable Single Cell Research
Market Chameleon (Wed, 29-Oct 5:54 AM ET)
PRNewswire (Wed, 29-Oct 9:00 AM ET)
PRNewswire (Mon, 20-Oct 12:30 PM ET)
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
PRNewswire (Thu, 9-Oct 4:05 PM ET)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
10X Genomics trades on the NASDAQ stock market under the symbol TXG.
As of December 31, 2025, TXG stock price climbed to $16.39 with 1,055,537 million shares trading.
TXG has a beta of 1.67, meaning it tends to be more sensitive to market movements. TXG has a correlation of 0.21 to the broad based SPY ETF.
TXG has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter 10X Genomics reported $149 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.07.
In the last 3 years, TXG traded as high as $63.57 and as low as $6.78.
The top ETF exchange traded funds that TXG belongs to (by Net Assets): ARKK, VTI, ARKG, VB, IWM.
TXG has underperformed the market in the last year with a return of +14.2%, while SPY returned +17.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TXG shares. However, TXG has outperformed the market in the last 3 month and 2 week periods, returning +40.2% and +4.3%, while SPY returned +2.8% and +0.8%, respectively. This indicates TXG has been having a stronger performance recently.
TXG support price is $15.74 and resistance is $16.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXG shares will trade within this expected range on the day.